ABBVIE
🇫🇷France
BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2019-05-31
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 159
- Registration Number
- NCT02047110
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2016-09-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 47
- Registration Number
- NCT02033551
- Locations
- 🇪🇸
Site Reference ID/Investigator# 117451, Madrid, Spain
🇺🇸Site Reference ID/Investigator# 117415, San Antonio, Texas, United States
🇳🇱Site Reference ID/Investigator# 117338, Maastricht, Netherlands
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-01-10
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 634
- Registration Number
- NCT02032277
- Locations
- 🇺🇸
Lehigh Valley Health Network /ID# 133372, Allentown, Pennsylvania, United States
🇺🇸Texas Oncology - Medical City Dallas /ID# 126141, Dallas, Texas, United States
🇺🇸UT Southwestern Medical Center /ID# 133849, Dallas, Texas, United States
Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2018-11-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 121
- Registration Number
- NCT02031276
To Observe the Impacts of Anti-Tumor Necrosis Factor (TNF) Effectiveness on Improvement in Work Place and Household Productivity for Patients With Psoriatic Arthritis (PsA)
Completed
- Conditions
- First Posted Date
- 2014-01-07
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 120
- Registration Number
- NCT02028169
Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 363
- Registration Number
- NCT02023099
Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 171
- Registration Number
- NCT02023112
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-12-20
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 217
- Registration Number
- NCT02016482
Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children With Synagis®
Completed
- Conditions
- First Posted Date
- 2013-12-20
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 312
- Registration Number
- NCT02016690
Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2018-05-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 30
- Registration Number
- NCT02015793
© Copyright 2024. All Rights Reserved by MedPath